Experimental cancer drug INCB062079 tested in 25 patients, study halted early
NCT ID NCT03144661
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This early-phase study tested the safety of a new drug, INCB062079, in 25 people with advanced liver cancer or other solid tumors. The goal was to find a safe dose and see how well patients tolerated the treatment. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University Hospital (UZ) Leuven
Leuven, 3000, Belgium
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of Toledo Medical Center
Toledo, Ohio, 43614, United States
Conditions
Explore the condition pages connected to this study.